A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review
<b>Background</b>: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/10/8/146 |
| _version_ | 1797559369914646528 |
|---|---|
| author | Caterina Monari Valeria Gentile Clarissa Camaioni Giulia Marino Nicola Coppola Vanvitelli COVID-19 group |
| author_facet | Caterina Monari Valeria Gentile Clarissa Camaioni Giulia Marino Nicola Coppola Vanvitelli COVID-19 group |
| author_sort | Caterina Monari |
| collection | DOAJ |
| description | <b>Background</b>: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? <b>Methods</b>: Our narrative review, developed using MEDLINE and EMBASE, summarizes the main evidences in favor or against the current proposed treatment regimens for COVID-19, with a particular focus on antiviral agents. Results: Although many agents have been proposed as possible treatment, to date, any of the potential drugs against SARS-CoV-2 has shown to be safe and effective for treating COVID-19. Despite the lack of definitive evidence, remdesivir remains the only antiviral with encouraging effects in hospitalized patients with COVID-19. <b>Conclusions</b>: In such a complex moment of global health emergency, it is hard to demand scientific evidence. Nevertheless, randomized clinical trials aiming to identify effective and safe drugs against SARS-CoV-2 infection are urgently needed in order to confirm or reject the currently available evidence. |
| first_indexed | 2024-03-10T17:44:24Z |
| format | Article |
| id | doaj.art-ee436ebc7cb846d2904eca3de06fd9ec |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T17:44:24Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-ee436ebc7cb846d2904eca3de06fd9ec2023-11-20T09:36:08ZengMDPI AGLife2075-17292020-08-0110814610.3390/life10080146A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative ReviewCaterina Monari0Valeria Gentile1Clarissa Camaioni2Giulia Marino3Nicola Coppola4Vanvitelli COVID-19 group5Department of Mental Health and Public Medicine—Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, ItalyDepartment of Mental Health and Public Medicine—Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, ItalyDepartment of Mental Health and Public Medicine—Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, ItalyDepartment of Mental Health and Public Medicine—Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, ItalyDepartment of Mental Health and Public Medicine—Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, ItalyDepartment of Mental Health and Public Medicine—Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy<b>Background</b>: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? <b>Methods</b>: Our narrative review, developed using MEDLINE and EMBASE, summarizes the main evidences in favor or against the current proposed treatment regimens for COVID-19, with a particular focus on antiviral agents. Results: Although many agents have been proposed as possible treatment, to date, any of the potential drugs against SARS-CoV-2 has shown to be safe and effective for treating COVID-19. Despite the lack of definitive evidence, remdesivir remains the only antiviral with encouraging effects in hospitalized patients with COVID-19. <b>Conclusions</b>: In such a complex moment of global health emergency, it is hard to demand scientific evidence. Nevertheless, randomized clinical trials aiming to identify effective and safe drugs against SARS-CoV-2 infection are urgently needed in order to confirm or reject the currently available evidence.https://www.mdpi.com/2075-1729/10/8/146COVID-19antiviral therapyearly phasecurrent evidencescurrent recommendationsmanagement |
| spellingShingle | Caterina Monari Valeria Gentile Clarissa Camaioni Giulia Marino Nicola Coppola Vanvitelli COVID-19 group A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review Life COVID-19 antiviral therapy early phase current evidences current recommendations management |
| title | A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review |
| title_full | A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review |
| title_fullStr | A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review |
| title_full_unstemmed | A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review |
| title_short | A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review |
| title_sort | focus on the nowadays potential antiviral strategies in early phase of coronavirus disease 2019 covid 19 a narrative review |
| topic | COVID-19 antiviral therapy early phase current evidences current recommendations management |
| url | https://www.mdpi.com/2075-1729/10/8/146 |
| work_keys_str_mv | AT caterinamonari afocusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT valeriagentile afocusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT clarissacamaioni afocusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT giuliamarino afocusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT nicolacoppola afocusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT vanvitellicovid19group afocusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT caterinamonari focusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT valeriagentile focusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT clarissacamaioni focusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT giuliamarino focusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT nicolacoppola focusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview AT vanvitellicovid19group focusonthenowadayspotentialantiviralstrategiesinearlyphaseofcoronavirusdisease2019covid19anarrativereview |